RNAi Therapeutics Market is projected to grow at an annualized rate of ~45%, till 2030

January 8, 2021

Roots Analysis has done a detailed study on RNAi Therapeutics Market (2nd Edition), 2019 – 2030: Focus on siRNA, miRNA, shRNA and DNA, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.


To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link


Key Market Insights

  • Over 32,000 patents related to RNAi therapeutics, indicating the heightened pace of research, have been filed / granted in the last several years
  • Presently, there is only one approved drug and over 150 product candidates, which are being evaluated for the treatment of a variety of disease indications, based on the RNAi principle
  • In order to achieve a competitive edge, the drug developers are increasingly focusing on developing the robust pipeline molecules across different therapeutic areas
  • Majority of the candidate therapies are currently in the early stages of development and are based on the siRNA approach; the innovation in this domain is being led by developers headquartered in the US
  • Several trials evaluating various RNAi drug candidates against a wide range of therapeutic indications have been registered in the recent past
  • Investors, having realized the opportunity within this emerging segment of the pharmaceutical industry, have invested over USD 5 billion in capital across 65 instances, in the period between 2014 and 2019
  • The increasing interest in this field is reflected in recent partnership activity; majority of deals inked were R&D and licensing agreements, featuring the participation of both international and indigenous stakeholders
  • In order to keep patients and healthcare professionals informed and aware of the developments in this field of medicine, companies are deploying diverse promotional strategies for their respective products
  • Prevalent trends indicate that the market for RNAi therapeutics is poised to grow significantly as multiple late stage molecules are commercialized in the near future, for the treatment of different clinical conditions


For more information, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415


Article Categories:

Leave a Comment